Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as $2.1 billion to next-gen delivery mechanisms for its metabolic portfolio.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as $2.1 billion to next-gen delivery mechanisms for its metabolic portfolio.